Artivion’s Endospan acquisition puts NEXUS at the centre of aortic arch device competition
Artivion now owns NEXUS. The bigger test is whether FDA approval can become a scalable U.S. aortic arch business.
Artivion just bought a bigger aortic future, but investors may not love the waiting game
Artivion’s aortic portfolio is getting stronger, but its 2026 outlook is getting weaker. Can Endospan turn strategy into growth?
NEXUS gets FDA approval: can Endospan finally crack the hardest segment in endovascular aortic repair?
Endospan’s FDA-approved NEXUS system could reshape high-risk aortic arch repair. Read what the approval changes and what clinicians will watch next.
CE Mark clearance for BD Revello stent highlights growing competition in endovascular PAD therapies
BD secures EU CE Mark for the Revello vascular covered stent for iliac artery disease. Explore what this device could change for PAD treatment in Europe.
Profusa Lumee Oxygen gains pre-approval orders as EU MDR decision looms
Profusa secures Lumee Oxygen orders ahead of EU MDR clearance. Discover what this means for CLTI monitoring and 2026 commercialization.
Why Philips LumiGuide could disrupt image-guided therapy with real-time light-based 3D navigation
Philips expands LumiGuide AI 3D light-based navigation across US and Europe. Find out how it could reshape image-guided therapy without radiation.